Publications

Brack S., Attinger-Toller I., Schade B., Mourlane F., Klupsch K., Woods R., Hachemi H., von der Bey U., Koenig-Friedrich S., Bertschinger J., Grabulovski D. (2014) A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action. Mol Cancer Ther. 13(8), 2030-2039.
Article >>

Silacci M., Baenziger-Tobler N., Lembke W., Zha W., Batey S., Bertschinger J., Grabulovski D. (2014) Linker length matters: Fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency. J Biol Chem. 289(20) 14392-14398.
Article >>

Banner D.W., Gsell B., Benz J., Bertschinger J., Burger D., Brack S., Cuppuleri S., Debulpaep M., Gast A., Grabulovski D., Hennig M., Hilpert H., Huber W., Kuglstatter A., Kusznir E., Laeremans T., Matile H., Miscenic C., Rufer A.C., Schlatter D., Steyaert J., Stihle M., Thoma R., Weber M., Ruf A. (2013) Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones. Acta Crystallogr D Biol Crystallogr. 69(Pt 6), 1124-1137.
Article >>

Schlatter D., Brack S., Banner D.W., Batey S., Benz J., Bertschinger J., Huber W., Joseph C., Rufer A., van der Klooster A., Weber M., Grabulovski D., Hennig M. (2011) Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain. MAbs. 4(4), 497-508.
Article >>

Bertschinger J., Grabulovski D. and Neri D. (2007) Selection of single domain binding proteins by covalent DNA display. Protein Eng Des Sel. 20(2), 57-68.
Article >>

Grabulovski D., Kaspar M. and Neri D. (2007) A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem. 282(5), 3196-3204.
Article >>

Posters

Woods R., Wuellner U., Buller F., Klupsch K., Brack S., Hachemi H., Zbinden I., Santimaria R., Attinger-Toller I., Koenig-Friedrich S., van der Bey U., Bertschiner J., Grabulovski D. (2014) Bispecific HER2/CD3 and EGFR/CD3 targeting FynomAbs with excellent tumor killing and favorable pharmacokinetic properties. ASCO meeting in Chicago, Abstract No. 3066.
Download Poster >>

Schade B., Brack S., Attinger-Toller I., Klupsch K., Woods R., Hachemi H., von der Bey U., König-­Friedrich S., Bertschinger J., Grabulovski D. (2014) COVA208, a bispecific HER2 targeting FynomAb with superior anti-tumor activity and novel mode of action. AACR meeting in San Diego, Abstract No: 658.
Download Poster >>

Wuellner U., Buller F., Klupsch K., Brack S., Zbinden I., Santimaria R., Attinger-Toller I., Koenig-Friedrich S., Bertschinger J., Grabulovski D. (2014) Bispecific HER2/CD3 and EGFR/CD3 targeting FynomAbs with excellent tumor killing and favorable pharmacokinetic properties. AACR meeting in San Diego, Abstract No. 656.
Download Poster >>

Grabulovski, D., Silacci, M., Baenziger-Tobler, N., Lembke, W., Zha, W., Woods, R., et al. (2013) COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha/Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic. Arthritis Rheum. 65 Suppl. 10:1219.
Download Poster >>

Locher, M., Grabulovski, D., Attinger-Toller, I., Koenig-Friedrich, S., Bey, U. von der, Bertschinger, J. (2013) COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha/Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys. Arthritis Rheum. 65 Suppl. 10:2225.
 Download Poster >>

Mourlane, F., Toller, I., Brack, S., Grabulovski, D., Bertschinger, J. (2012) Bispecific Fynomer-antibody fusion proteins targeting two epitopes on HER2. Journal of Clinical Oncology 30(15), Meeting Abstract 2575
Download Poster >>